ROR1 and B-cell chronic lymphocytic leukemia: As evidence of the therapeutic efficacy of miR-29 in CLL, in 2019 Chiang and colleagues developed an immuno-nanoparticle-based miR-29b delivery formulation with selectivity to CLL cells but not normal B cells thanks to its target to ROR1, which is expressed in 95% of CLL cells but not in normal B cells [53].